麻豆AV出品在线观看_偷偷鲁视频成人免费视频_乱子伦在线观看中文字幕_人碰人摸人爱免费视频在线观看

Search for the keyword:
   
Candesartan ester joint amiodarone in the treatment of atrial fibrillation clinical observation
source:Vitalpharms Company Ltd.    Release date:2017-12-6 10:17:08

Atrial fibrillation is one of the most common arrhythmia and myocardial structure in recent years, studies have shown that atrial fibrillation is a clear to refactor and electricity, and associated with excessive activation of renin angiotensin system. Application of amiodarone and guangdong candesartan ester share in the treatment of persistent af curative effect is satisfactory.

1, materials and methods

1.1 general data selection in March 2007 to December 2009 in the hospital, 65 cases of patients with persistent af, male 35 cases, 30 cases of female aged 60 ~ 82 years old, on average at the age of 74. Af duration 2 days to 3 months. Ultrasound not seen in the left atrial thrombus, answer law has the international standard with warfarin before ratio (INR) is set to 2.0 ~ 3.0, and maintain more than 3 weeks. Randomly divided into two groups, guangdong candesartan ester with amiodarone combined group of 35 cases, amiodarone group 30 cases. Answer law before the two groups of patients with gender, age, duration of atrial fibrillation, there was no statistically significant difference basic information such as blood pressure levels (P > 0.05), comparable.

1.2 methods specific usage: 1 week amiodarone 0.2 g, 3 times/d, week 2 to 0.2 g, 2 times/d, reduction of 0.2 g, 3 week 1 / d.

1.3 observe index (1) of the patient's symptoms, heart rate, heart rate and blood pressure change; (2) use of atrial fibrillation after successful rate and average converting time; (3) cases of recurrence; (4) the left atrial function.

1.4 statistical methods using SPSS11.0 software for statistical processing, with P < 0.05 for the difference was statistically significant.

2, the results

2.1 converting atrial fibrillation in the two groups have different medicine 1 case in 5 days sinus bradycardia (heart rate < 50 times/min) from the experiment. 50 patients completed 6 months of follow-up, joint group of 32 cases, 18 cases of amiodarone group. Joint group week successful rate was 67.6%, amiodarone group successful rate was 41.4%, two groups compare difference was statistically significant (P < 0.05); At the same time, the converting time of the joint group significantly reduced compared with amiodarone group, the difference was statistically significant (P < 0.05). Combination blood pressure than amiodarone group declined, but there was no statistically significant difference (P > 0.05).

2.2 joint group left atrial function changes after six months of color doppler follow-up of left atrial function in determination of prompt improvement, comparing with amiodarone group difference was statistically significant (P < 0.05).

3, discuss

Atrial fibrillation (af), is the heart is disorderly excitement and invalid contract room sex rhythm, is one of the most common clinical arrhythmia. Is an independent risk factor for hospital mortality increased, so you need to control the ventricular rate in atrial fibrillation as soon as possible, or converting it to sinus rhythm. Ideal therapeutic effect to maintain sinus rhythm of atrial fibrillation, reduce embolism events and to eliminate or reduce atrial remodeling.

In recent years, the mechanism of atrial fibrillation confirmed that atrial remodeling, including atrial remodeling and electrical remodeling, which is a key link in the process of af and maintain. Guangdong candesartan ester angiotensin receptor Ⅱ agent such as antagonism to electrical remodeling in atrial muscle inhibition may be related to prevention of atrial muscle intracellular calcium overload, which reduced the atrial continues to high frequency concussion middle of the back of the battery

Previous:The related substances of gamla SiQiong hydrochloride and applicability test/
Next:Rabeprazole sodium azole adverse reactions

About Us
Company Profile
Culture
Qualification
Staff style
Organization
News
Company News
Industry news
Media coverage
Products
Agent Products
Intermediates
Associated with the review and intermediates
Animal health related products
Merchants joined
Industry Standard
Quality certification
Contact Us
Vitalpharms Company Ltd.
Add.: 2/F, 3# Buliding, 169 Shihua Rd. West, Zhuhai, Guangdong, China.
Tel: +86-756-3326819/ 3221531
Fax: +86-756-3326816
E-MAIL: sales@www.palmbeachunited.com
Copyright©Vitalpharms Company Ltd.  Internet Drug Information Service Qualification Certificate: (Guangdong)- Non-operational -2023-0028   粵ICP備10097759號(hào)